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‘‘THREE PARENT BABIES”: TECHNIQUES
EXPLAINED, OBJECTIONS EXAMINED
Rebecca Carr*
The UK Parliament has approved regulations, which come into force in
October 2015, that permit the use of new treatment techniques to prevent the
transmission of serious mitochondrial diseases from women to their children.1
The introduction of these techniques—which are not currently carried out in any
country in the world—will fly in the face of the opposition that has been raised
since discussions to permit clinical applications of the techniques first arose.
After outlining some background to the techniques, this article briefly examines
three of the objections that have been made against them: that the safety and
effectiveness of the procedures have yet to be proven; that the procedures would
have an adverse socio-ethical impact; and that the procedures are prohibited in
international law. None of these objections are as strong as they appear to have
been suggested. Indeed, the UK Parliament’s approval of the regulations should
be welcomed.
I. MITOCHONDRIAL FUNCTION AND DISEASES
Mitochondria are the energy-producing organelles found in the cytoplasm of
every human cell.2 Any nutrition received by the body is converted into cellular
energy by the enzymes contained in these mitochondria,3 this energy being
essential for the functioning of cells. In particular, energy is required for cell
proliferation, movement, contraction, and the generation and processing of
signals for organ and tissue functioning.4 Furthermore, mitochondria also play a
role in the maturation of human gametes, embryonic development, and
programmed cell death.5
* Rebecca Carr LLB (Hons), LL.M.. The author wishes to thank Richard Owens for his
helpful comments on an earlier draft of this article.
1 HumanFertilisation andEmbryologyAct 2008 (U.K.), c. 22,TheHumanFertilisation and
Embryology (Mitochondrial Donation) Regulations 2015, S.I. 2015/572 [Mitochondrial
Donation Regulations].
2 U.K., Human Fertilisation and Embryology Authority, Scientific Review of the Safety
and Efficacy of Methods to Avoid Mitochondrial Disease through Assisted Conception
(2011) at 6, online: HFEA <www.hfea.gov.uk/docs/2011-04-18_Mitochondria_re-
view_-_final_report.PDF> [HFEA, 2011 Report].
3 Nuffield Council on Bioethics, Novel Techniques for the Prevention of Mitochondrial
DNADisorders: An Ethical Review (London, UK: Nuffield Council on Bioethics, 2012)
at 18 [NCB, Ethical Review].
4 Justin St John &Robin Lovell-Badge, ‘‘Human-Animal Cytoplasmic Hybrid Embryos,
Mitochondria, and an Energetic Debate” (2007) 9:9 Nature Cell Biology 988 at 990.
5 Li-yaWang et al, ‘‘Mitochondrial Functions onOocytes andPreimplantationEmbryos”
(2009) 10:7 J Zhejiang U Science B 483; HFEA, 2011 Report, supra note 2 at 7.
In humans, mitochondria are inherited maternally as individuals’
mitochondrial makeup derives entirely from the cytoplasm of their mother’s
egg.6 Mitochondrial diseases, therefore, are also inherited maternally. The
genetic structure comprising each mitochondrial DNA variant may differ and
can be defined as either homoplasmic or heteroplasmic. Where the mother’s
mutated mitochondrial DNA variant is homoplasmic, all her eggs will inherit
identical mitochondrial DNA.7 However, where multiple sequence variants exist:
[T]here is a possibility of unequal partitioning among oocytes, a
phenomenon known as the mitochondrial bottleneck, where a small
number of founder mtDNAs [(mitochondrial DNA)] can be over-
represented in the pool of mtDNAs of subsequent children, both
because some mitochondria may be transmitted preferentially and
because of the small sample size imposed by the bottleneck. Thus a
heteroplasmic mother with low to medium amounts of mutant mtDNA
can give birth to children with significantly higher levels of mutant
mitochondria.8
This makes it difficult to determine the true likelihood of a mother passing
on a heteroplasmic variant-derived mitochondrial DNA disease to her child,9
and renders the clinical prognosis for the child uncertain. To this extent,
mitochondrial DNA diseases have been described as ‘‘a cruel class of inherited
disease, because serious, even life-threatening conditions are coupled with great
unpredictability about how future children will be affected.”10 The clinical
symptoms of a mitochondrial disease are similarly diverse, owing to the manner
in which the disease may be inherited and to the often unique distribution of
6 U.S., Food and Drug Administration, Cellular, Tissue, and Gene Therapies Advisory
Committee, FDA Briefing Document: Oocyte Modification in Assisted Reproduction for
thePrevention of Transmission ofMitochondrialDisease or Treatment of Infertility (2014)
at 6, online: FDA <www.fda.gov/downloads/advisorycommittees/committeesmee-
tingmaterials/bloodvaccinesandotherbiologics/cellulartissueandgenetherapiesadvisor-
ycommittee/ucm385461.pdf> [FDA, Briefing Document]. The report notes, ‘‘[t]he
sperm mitochondria are actively degraded by ubiquitination” per Peter Sutovsky et al,
‘‘Ubiquitinated Sperm Mitochondria, Selective Proteolysis, and the Regulation of
Mitochondrial Inheritance inMammalian Embryos” (2000) 63:2 BiologyReproduction
582. Note that the process of ubiquitination is one which oversees the degradation of
cellular proteins—in this case of the sperm’s mitochondria which is used only in the
process of fertilizing the egg, upon which it degrades. In rare circumstances, male
mitochondrial DNA may enter the egg; however, this is very rare. See NCB, Ethical
Review, supra note 3 for more information.
7 FDA, Briefing Document, supra note 6 at 6.
8 Ibid [citations omitted].
9 Ibid at 6.
10 North East England StemCell Institute, Briefing Paper on the Need to Protect the Future
Possibility of Treating Mitochondrial Disease and Other Conditions by a Procedure that
Involves Mitochondrial Transplantation (Newcastle, U.K.: NESCI, 2008) at 2, online:
Newcastle University <www.ncl.ac.uk/nesci/assets/docs/NESCIbriefon2008HFEbill-
MitochondrialTransplants-Vers01-6.pdf>.
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affected genes within each cell.11 Known symptoms tend to become progressively
debilitating and include ‘‘poor growth, loss of muscle coordination, muscle
weakness, visual problems, hearing problems, learning disabilities, heart disease,
liver disease, kidney disease, gastrointestinal disorders, respiratory disorders,
neurological problems, autonomic dysfunction and dementia.”12
Currently, there is no cure for mitochondrial diseases, with most clinical
interventions aiming to manage the diseases’ unforgiving symptoms. For
heteroplasmic women, pre-implantation genetic diagnosis (PGD) sampling
methods detect which, if any, of their eggs appear to contain a lower level of
mitochondrial DNA mutations before implantation via in vitro fertilization
(IVF) techniques in order to minimize the risks of passing on a mitochondrial
DNA inherited condition. This option would not, however, guarantee the non-
transmission of a mitochondrial disease to the child (and if the child is female, to
her own future children), or be appropriate for women with homoplasmic
mutant mitochondrial DNA variants who necessarily transfer the genes that
result in disease.13
II. NEW MITOCHONDRIAL GENE TRANSFER TECHNIQUES
In light of these factors, researchers have sought to find a way to prevent
transmission of mitochondrial DNA diseases in their entirety—two new
experimental techniques have been put forward. The first, metaphase spindle
transfer (MST) ‘‘is the transfer of female nuclear genetic material from an oocyte
into an enucleated donor oocyte, containing normal mitochondria, followed by
IVF.”14 The second, pronuclear transfer (PNT) ‘‘is the transfer of the male and
female pronuclei from a fertilized oocyte (zygote) into a stage-matched
enucleated donor zygote, followed by IVF.”15 Either technique, if successful,
would prevent the transmission of mitochondrial DNA diseases from a woman
to her child, and would contain genetic material from three people—the mother’s
nuclear DNA, the father’s nuclear DNA, and the donor’s mitochondrial DNA.
If the proposed MST and PNT DNA transfer techniques are shown to be
successful in humans, their introduction into the clinical setting would represent
a scientific breakthrough for the families affected by these diseases. Children who
would have otherwise developed inherited mitochondrial DNA disorders will be
spared a lifetime of suffering and women carrying mutant mitochondrial DNA
11 Robert W Taylor & Doug M Turnbull, ‘‘Mitochondrial DNA Mutations in Human
Disease” (2005) 6:5 Nature Reviews Genetics 389.
12 Monkbot, ‘‘Mitochondrial Disease: Signs and Symptoms” in Wikipedia, The Free
Encyclopedia (Wikimedia Foundation, 2015), online: <https://en.wikipedia.org/wiki/
Mitochondrial_disease#Signs_and_symptoms>.
13 See NCB, Ethical Review, supra note 3 at 27-28.
14 FDA, Briefing Document, supra note 6 at 12.
15 Ibid.
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affected genes will still be able to maintain a genetic link with their child without
bearing the risks of transmission.
So what are some of the arguments that have been raised against the
techniques’ introduction, and do they carry any real weight?
III. OBJECTIONS
(a) That the Safety and Effectiveness of the Procedures have yet to be
Proven
Perhaps the most pressing of the objections raised thus far relate to the safety
and effectiveness of the techniques.
The main risks of the procedure appear to be those faced by the child and, to
some extent (as is explained later), the mother—although, since the techniques
involve genetic manipulation, there exists potential risks to future generations as
well.
There is a potential for inadvertent damage to be inflicted upon the
manipulated oocyte or embryo during transfer, since the mitochondria’s
distribution within each cell is thought to have some impact upon the process
of early embryogenesis that the transfer techniques are subsequently liable to
disturb.16 Also, since the developing fetus receives its nutritional, energy-based
needs from its mother, a long-term impact may arise from manipulating the
child’s mitochondria, which cannot be accurately detected before birth. Other
concerns include the possibility of mutant mitochondrial DNA being carried
over to the donor oocyte/embryo during transfer, and the risk of nuclear-
mitochondrial incompatibility from the donor oocyte/embryo.17 The potential
toxicity of the reagents used in conducting the transfer’s micromanipulation
techniques poses a further known risk to the child; however, some evidence
suggests that as long as care is taken, and given that the Medicines and
Healthcare Products Regulatory Agency would need to be satisfied about the
provenance and clinical safety of any such reagents first,18 it is thought their
eventual usage would not be problematic.19
16 Ibid at 16. Further, see Lyndsey Craven et al, ‘‘Mitochondrial DNA Disease: New
Options for Prevention” (2011) 20:R2 Human Molecular Genetics R168 at R170 who
somewhat concernedly points out that ‘‘[w]hile the wealth of evidence from mouse
studies indicates that pronuclear transfer is compatible with normal development,
evidence from human studies indicates a 50% reduction in the proportion of embryos
developing to the blastocyst stage,” although she also acknowledges that these were
abnormal zygotes to begin with. The evidence she is referring to is presented in Lyndsey
Craven et al, ‘‘Pronuclear Transfer in Human Embryos to Prevent Transmission of
Mitochondrial DNA Disease” (2010) 465:7294 Nature 82.
17 FDA, Briefing Document, supra note 6 at 18. This issue arises from the fact that ‘‘the
[mitochondrial DNA] of the recipient oocyte or embryo may be derived from a
mitochondrial haplotype different from the nuclear donor. Therefore, the potential for
nuclear-mitochondrial incompatibility. . .exists.”
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The safety of the mother and oocyte/embryo donor must also be considered.
Both will have to undergo ovarian stimulation to enable the transfer techniques
to take place. The US Food and Drug Administration’s Cellular, Tissue and
Gene Therapies Advisory Committee—a Committee which has decided not to
allow the clinical application of the techniques at present—has suggested risks to
the woman might include failure to become pregnant and/or deliver a child as
well as risks associated with the mitochondrial manipulation technology
procedure and risks pertaining to the toxicities of the reagents used in the
technologies.20 However, little research appears to have been conducted that
specifically looks at these issues from the perspective of the woman.
The Human Fertilisation and Embryology Authority (HFEA), the UK body
charged with undertaking the government’s scientific review into the safety and
efficacy of the proposed methods, while recognizing that ‘‘[r]esearch can never
answer every question before a new treatment is offered, nor can it be expected to
guarantee safety or efficacy when applied for the first time in the clinic,” confirms
that ‘‘the evidence available [in 2011 and 2013] did not suggest that [MST and
PNT] are unsafe.”21
The HFEA reviews—specifically commissioned by and to assist the
government—canvass the available evidence to provide an informative
overview of existing findings, and make suggestions on the areas that appear
to require further research.
The HFEA reviews suggest that many of the above-mentioned concerns can
be allayed. For example, they state that there is no evidence to suggest that
epigenetic alterations through MST or PNT, if they exist, ‘‘have any significant
or far reaching effect on development or health”22 and that once assessed as safe
to use in clinical practice, children born as a result of the techniques could be
followed up for an extensive period in order to assess any long term
impact—arguably the best way to obtain the most accurate results on the
matter. In relation to the potential for mitochondrial DNA carryover, the
HFEA’s 2014 review states ‘‘evidence presented to the panel in 2013 continues to
be reassuring that carryover after mitochondrial replacement is very low”23 and
that:
[I]f any uncertainty about the degree of heteroplasmy in oocytes
remains when women born as a result of MST or PNT wish to have
18 U.K., Human Fertilisation and Embryology Authority, ‘‘Third Scientific Review of the
Safety and Efficacy of Methods to Avoid Mitochondrial Disease through Assisted
Conception: 2014 Update” (2014) at 24, online: HFEA <www.hfea.gov.uk/docs/
Third_Mitochondrial_replacement_scientific_review.pdf> [HFEA, 2014 Report].
19 See HFEA, 2011 Report, supra note 2 at 18-19.
20 See FDA Briefing Document, supra note 2 at 20.
21 HFEA, 2014 Report, supra note 18 at 5.
22 Ibid at 34.
23 Ibid at 24.
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children, then either this should be examined directly in unfertilised
oocytes collected from the women obtained after stimulation, and/or
PGD should be carried out on fertilised embryos prior to selecting
those with, no or very low, levels of abnormal mtDNA for transfer.24
Finally, in relation to the potential risk of nuclear-mitochondrial
incompatibility arising from the donor oocyte/embryo, the HFEA, while
suggesting the risk is very low, recommends that as a precautionary step,
consideration should be given to mitochondrial DNA haplogroup matching,
drawing a parallel to the similar processes that are undertaken in organ
donation.25
In any event, and of key significance in this fast evolving field, the
overarching regulatory mandate of the HFEA, which governs all assisted
reproduction procedures that involve human gametes or embryos in the UK,
would ensure the necessary clinical safety of the techniques has been
demonstrated before applying the techniques to individual cases. The
introduction of the regulations, therefore, will not necessarily lead to the
techniques’ immediate roll out in clinical practice. Rather, it will give the HFEA
the power to allow the clinical application of these potentially life-saving
techniques, if and when it deems that such procedures are sufficiently safe.
(b) That the Procedures will have an Adverse Socio-Ethical Impact
The UK Parliament’s decision to pass the legislation, however, has rested on
more than science alone.26 The mitochondrial donation techniques raise a
number of socio-ethical issues that have also merited due consideration.
(i) Genetic Identity
One of the key sticking points of the techniques’ legalization debate thus far
has been over its potential creation of ‘‘three parent babies”—the term in itself
being a controversial coinage.
Since children born from the techniques would have a genetic connection to
three people—namely the mother, the father, and the mitochondrial DNA
donor—some may question whether the child’s sense of identity, in not truly
knowing this third genetic contributor, could be harmed and whether our current
conceptualizations of legal parenthood would, in turn, need to be revised. For
some, the argument is simply non sequitur: ‘‘it would be misleading to describe
children born following [M]ST or PNT as having biologically or legally, ‘three
parents’ or ‘two mothers’. Indeed the genetic contribution from the mtDNA
donor is small, constituting only 0.1% of the total DNA.”27
24 Ibid at 27.
25 Ibid at 5.
26 Ibid.
27 Shoukhrat Mitalipov & Don P Wolf., ‘‘Clinical and Ethical Implications of Mitochon-
drial Gene Transfer” (2014) 25:1 Trends in Endocrinology & Metabolism 5 at 7.
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In spite of the seeming statistical irrelevance of mitochondrial DNA, in
relation to one’s overall DNA makeup, some are understandably uncomfortable
with the various attempts that have been made to downplay its underlying role.
The fact that experimentation upon reproductive materials, as materials that
contain the very essence of our genetic destiny are even meriting of their own set
of regulations, suggests that these materials are in fact significant, perhaps
precisely because of their genetic content and capabilities.
The fact that a child could therefore have a materially relevant genetic
connection to three persons (or parents, perhaps by definition), is not, however, a
sufficient reason to prevent the clinical application of the proposed techniques.
Conceptions of the family and of parenthood are extremely fluid and have been
recognized in law as such.28 It is assumed that most donors will not request the
recognition of their parentage, and that, by and large, it would not be in the
child’s best interests to recognize this third person’s status as that of a legal
parent. Indeed, the regulations expressly prohibit donors from applying for a
parental order on the basis of their mitochondrial DNA donation alone.29
One could imagine certain cases, however, where it could be appropriate to
recognize a genetic donor’s legal parentage; for example, where two women
intending to raise the child contribute to the child’s genetic makeup30 with the
help of a known sperm donor who wishes to remain involved in the child’s life.31
Similar circumstances arose in the Ontario Court of Appeal’s decision in A. (A.)
v. B. (B.),32 where the Court ruled that ‘‘allowing a child to have three registered
legal parents”33 ‘‘could bridge a ‘legislative gap’ in the Children’s Law Reform
Act 1990.”34 The UK House of Lords (now the UK Supreme Court) has also
emphasized the significance of recognizing different kinds of legal parentage,35
28 See, e.g, the case ofG.,Re, [2006]UKHL43 (U.K.H.L.)BaronessHale states, “There are
at least threeways inwhich apersonmaybe or become anatural parent of a child, each of
which may be a very significant factor in the child’s welfare, depending upon the
circumstances of the particular case. The first is genetic parenthood. . ..The second is
gestational parenthood. . ..The third is social and psychological parenthood.”
29 Mitochondrial Donation Regulations, supra note 1, s. 18.
30 In relation to this fact scenario, however, Françoise Baylis questions whether it could
arise as a result of less therapeutically aimed goals. She says, ‘‘it could be used to pursue
non-therapeutic reproductive goals—imagine, a lesbian couple where both partners
wanted a genetic link to the children they intend to parent”: Françoise Baylis, ‘‘The
Ethics of Creating Children with Three Genetic Parents” (2013) 26:6 Reproductive
BioMedicine Online 531 at 533.
31 In line with provisions of the current Human Fertilisation and Embryology Act,
however, either the genetic father or female partner would have to forfeit their legal
parenthood. See Human Fertilisation and Embryology Act 2008.
32 A. (A.) v. B. (B.), 2007 ONCA 2, 2007 CarswellOnt 2 (Ont. C.A.).
33 Julie McCandless & Sally Sheldon, ‘‘The Human Fertilisation and Embryology Act
(2008) and the Tenacity of the Sexual Family Form” (2010) 73:2 Modern L Rev 175 at
192.
34 Ibid.
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and of the need for such recognition to be available, in order to serve children’s
various welfare needs.
The fact that a child could—in appropriate circumstances—come to have
three parents, is arguably not at odds with the way that many families ultimately
choose to raise their children—with multiple adults playing significant parent-
like roles in their lives.
(ii) The Ethics of Human Enhancement
In altering the DNA content of an individual at the early embryonic stage of
life, and in artificially fashioning the elements of their future being, some would
argue that the proposed techniques will tamper with the very essence of what it is
to be human—itself the subject of core beliefs, disagreement, and faith.
The natural state of affairs is held to be morally significant within a number
of different arenas.36 From a theological perspective, respect for each individual
human life and for the natural state that its maker has intended for it to be is
intimately bound with the idea of the sanctity of human life. On this view, all
human lives are inviolable and any interference with their natural sacrosanctity is
immoral. In the democratic realm, however, religious dogmas are often dismissed
as pious and irrelevant, particularly where science and its objective truths often
appear able to provide a more reasonable and enlightened response.
However, inherent reverence for human nature resonates with a genre of
more secular philosophies as well. Harvard’s Michael Sandel writes:
If bioengineering made the myth of the ”self-made man” come true, it
would be difficult to view our talents as gifts for which we are indebted,
rather than as achievements for which we are responsible. This would
transform three key features of our moral landscape: humility,
responsibility, and solidarity.37
On this view, our natural desires for human perfection through enhancement
must be mediated by a measure of respect for the natural gift of life with which
we have been endowed, if we are to avoid a ‘‘one-sided triumph of willfulness
over giftedness, of dominion over reverence, of molding over beholding.”38 Erik
Parens characterizes the nature of the debate as fitting within two different but
related frameworks of gratitude and creativity—the former emphasizing ‘‘our
obligation to remember that life is a gift and that we need to learn to let things
be,” and the latter ‘‘emphasiz[ing] our obligation to transform that gift and to
exhibit our creativity.”39 Both frameworks, he says, aspire towards achieving
35 G., Re, supra note 28.
36 Gregory E Kaebnick,Humans in Nature: The World as We Find It and the World as We
Create It (Oxford: Oxford University Press, 2014) at ix.
37 Michael J Sandel, ‘‘The Case against Perfection,” The Atlantic (April 2004), online:
<www.theatlantic.com>.
38 Michael J Sandel, The Case against Perfection: Ethics in the Age of Genetic Engineering
(Cambridge, MA: Belknap Press, 2007) at 85.
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authenticity—towards helping us to truly ‘‘‘become who we are.’”40 Thus, while
the adaptations the proposed techniques will likely inflict upon one’s human
nature give rise to ostensibly conflicting ethical considerations, these
considerations may be reconciled by justifying the techniques as means of
realizing the dignity of the concerned individuals’ authentic selves.
(iii) The ‘‘Slippery Slope”
Ethical objections to the techniques also coincide with more pragmatic
considerations. While the reasons currently underpinning the proposed
techniques appear wholesome, some argue that given that ‘‘[t]here simply is no
defensible way to draw a hard, bright line between medicine and eugenics . . .
[which] provides a spectrum, from preventing disease to maximizing health to
genetic enhancement,”41 we need to draw lines in ways that are most able to
protect the values and principles that we, as a society, wish to safeguard.42 That
is, if we do not believe that it is possible to ‘‘defend a ‘new’ morally
defensible—or perhaps even praiseworthy—eugenics that is distinct from and
will not lead to the ‘old’, bad, Nazi, and Fabian eugenics,”43 we need to make
legal distinctions that, although they may inevitably harm some through the
denial of particular treatments, will better serve the individual rights and dignity
of peoples in the long run.
Given the unknown and evolving technologies that future societies will likely
have at their disposal, however, it arguably does not make sense to limit the
current potential of this new biotechnological discovery that—with a clear legal
framework (as has been propounded) and regulatory oversight (that the HFEA is
both able and mandated to provide)—could be used responsibly in order to
prevent some of the suffering that is experienced today.
39 Erik Parens, ‘‘Authenticity andAmbivalence: TowardUnderstanding the Enhancement
Debate” (2005) 35:3 Hastings Center Report 34 at 38.
40 Ibid.
41 Nathaniel Comfort, ‘‘Three-parent Babies and Eugenics,” (March 2014), Genotopia:
Here Lies Truth (blog), online: <genotopia.scienceblog.com/date/2014/03>.
42 In drawing any lines, it is important to pay attention to the particular circumstances of
the issue at hand. ThomasMurray, for instance, articulates the oftenmisguided quest for
the ethics of enhancement that is a ‘‘problem. . .with the definite article ‘the,’ denoting a
singular all-purpose ethics for every form of human enhancement. . ..the ethics of
enhancement is deeply dependent on context. . .. [that is,] what is important about a
particular context is [to] elucidate[e] the values that are sought in or served by that sphere
of humanendeavor.”Theboundaries of enhancement should therefore be determinedby
the values inherent to the sphere. See Thomas Murray, ‘‘The Misguided Quest for the
Ethics of Enhancement” in Akira Akabayashi, ed, The Future of Bioethics: International
Dialogues (Oxford: Oxford University Press, 2014) 193 at 193.
43 Robert Sparrow, ‘‘Ethics, Eugenics, and Politics” in Akabayashi, supra note 42, 139 at
139.
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(c) That the Techniques are Prohibited in International Law
In October 2013, a group of 34 MPs of the Council of Europe, an
organization representing EU and non-EU signatories to the European
Convention on Human Rights, described the effects of the proposed
techniques as ‘‘incompatible with human dignity and international law.”44 At
first glance, their statement is persuasive. Article 2(b) of the Universal
Declaration on the Human Genome and Human Rights, for example, states that
‘‘dignity makes it imperative not to reduce individuals to their genetic
characteristics and to respect their uniqueness and diversity”45—ostensibly
things the techniques could serve to threaten. Furthermore, article 13 of the
Council of Europe’s Oviedo Convention46 states that any ‘‘intervention seeking
to modify the human genome may only be undertaken for preventive, diagnostic
or therapeutic purposes and only if its aim is not to introduce any modification in
the genome of any descendants”47—which is again, seemingly at odds with the
effects the new techniques are likely to produce.
Taking a broad view, however, while article 13 of the Oviedo Convention
prohibits interventions aiming to introduce modifications to the human genome
of future descendants, by applying the bioethical principle of the ‘‘doctrine of
double effect,”48 one could argue that since the primary purpose of the proposed
techniques is to introduce some measure of therapeutic benefit to an individual, it
would not fall afoul of current international standards, since its likely effect of
changing the genomic gene line (the potential ‘‘harm” in question) is not the
primary purpose of the technique. More persuasively, however, article 1 of the
Additional Protocol to the Oviedo Convention qualifies its provision that ‘‘[a]ny
intervention seeking to create a human being genetically identical to another
human being, whether living or dead, is prohibited,”49 to confirm that ‘‘the term
44 Council of Europe, PA, 2013 Ordinary Sess (Fourth Part), Creation of Embryos with
GeneticMaterial fromMore than Two Progenitor Persons,WrittenDeclarationNo. 557,
Doc No. 13325 (2013).
45 Universal Declaration on the Human Genome and Human Rights, UNESCOR, 1997, UN
Doc A/RES/53/152, art 2(b).
46 Council of Europe, PA,Convention for the Protection ofHumanRights andDignity of the
Human Being with regard to the Application of Biology and Medicine: Convention on
Human Rights and Biomedicine, CETS No. 164 (1997) [CE, Oviedo Convention].
47 Ibid, art 13.
48 The doctrine of double effect principle is one that would enable doctors, for example, to
administer large doses of pain relieving drugs to a patient, if their primary purpose for so
doing is to relieve the individual’s pain—irrespective of any inevitable side-effect of a
more hastened death. For a more detailed explanation, see AlisonMcIntyre, ‘‘Doctrine
of Double Effect” in Stanford Encyclopedia of Philosophy (Stanford, CA: Stanford
University, 2014), online: <http://plato.stanford.edu/entries/double-effect>.
49 Council of Europe, PA, Additional Protocol to the Convention for the Protection of
Human Rights and Dignity of the Human Being with regard to the Application of Biology
andMedicine, on theProhibition ofCloningHumanBeings, CETSNo. 168 (1998), art 1(1)
[CE, Additional Protocol].
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human being ‘genetically identical’ to another human being means a human
being sharing with another the same nuclear gene set.”50 The Convention
(uncharacteristically of many human rights instruments, which tend to be vague
and principled), in specifically delimiting the prohibition to interventions upon
the nuclear component of the cell, leaves open the possibility for interventions to
be made using the mitochondrial component of a cell—which is confirmed in a
Council of Europe explanatory report to the additional protocol.51
Mitochondrial DNA transfer techniques are, in other words, not prohibited
by international law. Conversely, and as David Lawrence argues, the use and
application of human enhancement technologies appears ‘‘thoroughly defended
in the canon of international human rights law, particularly under the
fundamental rights to health, scientific progress and the enablement of the
self.”52
IV. CONCLUSION
In 2015, the UK Parliament voted to legalize regulations that will permit the
clinical application of the mitochondrial DNA transfer techniques this article has
discussed. While a number of objections have been made against the techniques’
introduction, this article has sought to show that the objections relating to the
safety and efficacy of the techniques, to their socio-ethical impact, and to their
conformity with international legal standards are perhaps not as strong as they
may at first appear. The benefit that the proposed techniques appear to
offer—the potential for children of individuals with serious inheritable
mitochondrial DNA disorders wishing to have genetically related children to
be spared often intolerable (but now seemingly preventable) suffering—should be
welcomed. It is an extraordinary scientific feat that Parliament was correct to
welcome.
50 Ibid, art 1(2).
51 Council of Europe, PA, Additional Protocol to the Convention on Human Rights and
Biomedicine on theProhibition ofCloningHumanBeings:ExplanatoryReport, CETSNo.
168 (1998) at para 7, online: <conventions.coe.int/Treaty/EN/Reports/Html/
168.htm>.
52 David R Lawrence, ‘‘ToWhat Extent Is the Use of Human Enhancements Defended in
International Human Rights Legislation?” (2013) 13:4 Medical L Intl 254 at 278.
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